Figure 2

Inhibition of various melanoma cell lines by BAY43-9006 and rapamycin. A, The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells was assayed in triplicate by Cell Titer Glo (Promega; Madison, WI). Inhibition was determined as the difference between the number of cells in the control without any added drug compared to the number of cells following treatment with an inhibitor. Cells were treated for one hour with doses of BAY43-9006 ranging from 0.01 nM to 100 nM and were assayed for serum-stimulated proliferation after 48 hours. The mean value for triplicate samples from three independent experiments is plotted relative to the control (treated with vehicle, DMSO). Error bars are present at each point on the graph. The Student T test was performed and the bracket and asterisk represents a statistically significant difference between VMM39 (wt) and VMM5A (V599E) and VMM18 (V599E) cells at the 10 nM concentration with a p value < 0.002. B, The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells were assayed as described above except melanoma cells were treated with rapamycin instead of BAY43-9006 with doses ranging from 0.01 nM to 100 nM. The mean value for triplicate samples from three independent experiments is plotted. Error bars are present at each point on the graph. The Student T test was performed and the bracket and asterisk represents a statistically significant difference between VMM39 (wt) and VMM5A (V599E) and VMM18 (V599E) cells at the 10 nM concentration with a p value < 0.002.